Anteotech Ltd · ASX:ADO
Anteotech — Shareholder Meeting (November 2025)
23 slides from Anteotech's shareholder meeting presentation, Nov 26, 2025
Slide 1: Managing Director & CEO Presentation (ASX announcement)
ASX: ADO MANAGING DIRECTOR & CEO PRESENTATION BRISBANE, AUSTRALIA, 26 November 2025: AnteoTech Ltd’s Managing Director & CEO, Merrill Gray, will present the attached presentation at its Annual General Meeting today. This announcement has been authorised for release by the Board of AnteoTech Ltd. - E
Slide 2: 2025 Annual General Meeting
For personal use only 2025 Annual General Meeting Merrill Gray Managing Director & CEO Presentation 26 November 2025 COMMERCIAL-IN-CONFIDENCE This document is the property of AnteoTech Ltd and shall not be communicated to third parties and/or reproduced without prior written agreement. © Its content
Slide 3: Disclaimer
Disclaimer IMPORTANT INFORMATION For personal use only The purpose of the presentation is to provide an update of the business of AnteoTech Ltd (ASX:ADO) (AnteoTech). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or cl
Slide 4: Agenda
Agenda For personal use only • Welcome and overview • Our products and technology • Our plans and progress • Questions 25 November 26 November 2025 ©AnteoTech Limited 3 2025
Slide 5: Overview
Overview • AnteoTech Ltd (ASX: ADO) is a chemical and materials company with global sales and an expanding customer For personal use only base. • The Company is in the commercialisation stage of growth across both its Life Sciences and Advanced Battery Technologies business units. • AnteoTech’s core
Slide 6: AnteoBind product suite
LIFE SCIENCES The AnteoBind product suite is made up of: 1 AnteoBind NXT TM For personal use only • Delivers lower cost, higher performing (more sensitive 2 and reliable) immunodiagnostic tests, AnteoBind TM Biosensor across lateral flow and chemiluminescence (CLIA) • Supporting the development of f
Slide 7: Our Competitive Advantage in Immunoassays
LIFE SCIENCES Our Competitive Advantage in Immunoassays Superior Performance For personal use only Delivers up to a 45-fold improvement in detection compared to EDC/NHS (the industry standard). Simplified Workflow Features a one-step activation process, reducing variability and process complexity. C
Slide 8: Serum Institute of India (SII)
LIFE SCIENCES Serum Institute of India (SII) The world's largest manufacturer of vaccines and immuno-biologicals including vaccines for Diphtheria, Measles, Mumps, Rubella and Hepatitis-B, supplied globally and headquartered in Pune, Maharashtra, India. For personal use only • Global Impact: Three o
Slide 9: Leading in High Silicon Anode Technology
ADVANCED BATTERY TECHNOLOGIES Leading in High Silicon Anode Technology For personal use only ADDITIVE ULTRA HIGH "CROSS LINKER" SILICON ANODE – DROP IN TECHNOLOGY CHEMICAL FORMULATION 26 25 November 2025 ©AnteoTech Limited AnteoTech Proprietary & Confidential 8 8
Slide 10: Anteo X – A Cross-Linking Chemical Additive
ADVANCED BATTERY TECHNOLOGIES Anteo X – A “Cross-Linking” Chemical Additive Supports sustained anode performance by providing structural integrity For personal use only Sustainable and Versatile • Water-based and PFAS-free • Compatible with a wide range of binders • Easily integrated into existing m
Slide 11: Ultranode is Highly Customisable by Application
ADVANCED BATTERY TECHNOLOGIES Ultranode is Highly Customisable by Application Ultranode 95 Ultranode 70 Ultranode X For personal use only Target • High energy, lower cycle-life • Balances energy density with • 1,020 cycles at 80% capacity Applications uses such as Unmanned attractive cycle-life rete
Slide 12: Ultranode X – 1,020 cycles at 80% capacity retention achieved
ADVANCED BATTERY TECHNOLOGIES Ultranode X – 1,020 cycles at 80% capacity retention achieved Cathode: NMC532 – 3.6 mAh/cm2 Testing protocol: 1C CCCV & 1C CC at 25˚C Ultranode X – Capacity retention Electrolyte: 1M LiPF6 + FEC For personal use only 120 Voltage window: 4.2 -2.85 V Capacity retention (%
Slide 13: Ultranode Manufacturing Scale-up and Commercial Evaluation
Ultranode 70 Manufacturing Scale-up and Commercial Evaluation Wyon AG is a private Swiss company specialising in custom-shaped and custom-built, miniature and For personal use only micro rechargeable batteries. Wyon is considered a market leader in rechargeable batteries for use in medical technolog
Slide 14: Strategy by Target Markets
June 2025 Strategy by Target Markets Existing markets where opportunities will continue to be pursued New opportunities to be targeted and pursued Strategy Life Sciences Advanced Battery Technologies For personal use only India • Drive targeted sales growth through • Further expand through the Serum
Slide 15: The Foundations
The Foundations • Highly technically skilled workforce with a strong track record of innovation in Life Sciences. For personal use only • Anteo X Pilot Plant completed, with current capacity of 20,000 litres per year and scalability to 80,000 litres per year. • $6 million in Federal and State grant
Slide 16: Where We Are Now
Where We Are Now A leaner, more efficient, and more commercially focused Company For personal use only ~$1.6M in $2.6M R&D Tax Client Participant in Retention of the New leadership annualised cost Incentive Relationship Austrade’s ARENA grant with commercial savings delivered received. Management Ex
Slide 17: Accelerating Commercialisation Focus
Accelerating Commercialisation Focus Following a clear market-opportunity and demand-driven pathway and placing customers first For personal use only FY 24/25 was a reset year, with a growing AnteoTech is evolving into a commercially focus on sales processes and sales focused business. conversion in
Slide 18: Global Relevance Amid Market Shifts
Global Relevance Amid Market Shifts Significant new opportunities are emerging For personal use only • Chinese export controls • Incorporating more • In the Life Sciences • Point-of-care (POCT) or are tightening on silicon into batteries business, the use testing is graphite and other can deliver th
Slide 19: Summary – Commercial Execution Progression
Summary – Commercial Execution Progression We have delivered and will continue to deliver against our Strategic Review objectives US market entry with Progress with AnteoBind NXT Work is Critically, we For personal use only carbon nanotube joint Wyon on selected for continuing on continue to: produc
Slide 20: Appendices
For personal use only Appendices 26 November AnteoTech Proprietary & Confidential 2024 AnteoTech Annual General Meeting 19
Slide 21: Where AnteoTech Participates in the LiB Supply Chain
ADVANCED BATTERY TECHNOLOGIES Where AnteoTech Participates in the LiB Supply Chain UPSTREAM MIDSTREAM DOWNSTREAM LiB LiB MINING/CHEMICALS COMPONENT LiB ASSEMBLY END LiB USE MATERIALS PRODUCTION For personal use only Newly mined raw materials Processing/ Anode LiB manufacture – End Use • Hard rock &
Slide 22: Overall Life Sciences Market View
LIFE SCIENCES Overall Life Sciences Market View AnteoTech currently does not operate in these Life Sciences sub sectors Global In Vitro Diagnostics (IVD) Pharmaceutical Biotechnology Medical Devices For personal use only AnteoTech does not operate here Proteins, polymers, antibodies, etc. DNA RNA IM
Slide 23: AnteoTech's Life Sciences Market Value/Size & Growth
LIFE SCIENCES AnteoTech’s Life Sciences Market Value/Size & Growth All figures in US$ billions as at 2024 Global In Vitro Diagnostics (IVD) Market Value: + $100 B, +7% CAGR to 2029 (9% APAC) For personal use only Proteins, polymers, antibodies, etc. IMMUNOASSAYS including Molecular Diagnostics Marke